UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 3, 2010
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES x NO o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES x NO o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer x
Accelerated filer o
Non-accelerated filer o
Smaller reporting company o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES o NO x
At November 8, 2010, 8,009,951,287 shares of the issuer s voting common stock were outstanding.
FORM 10-Q
For the Quarter Ended
October 3, 2010
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and nine months ended October 3, 2010, and September 27, 2009
Condensed Consolidated Balance Sheets as of October 3, 2010, and December 31, 2009
Condensed Consolidated Statements of Cash Flows for the nine months ended October 3, 2010, and September 27, 2009
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
22
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
23
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
57
Item 4.
Controls and Procedures
57
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
57
Item 1A.
Risk Factors
60
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
60
Item 3.
Defaults Upon Senior Securities
60
Item 5.
Other Information
60
Item 6.
Exhibits
61
Signature
62
PART I FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(millions, except per common share data)
Oct. 3,
2010
Sept. 27,
2009
Oct. 3,
2010
Sept. 27,
2009
Revenues
16,171
11,621
50,248
33,472
Costs and expenses:
Cost of sales(a)
3,896
1,789
11,997
4,953
Selling, informational and administrative expenses(a)
4,633
3,282
13,876
9,508
Research and development expenses(a)
2,194
1,632
6,607
5,032
Amortization of intangible assets
1,156
594
3,972
1,755
Acquisition-related in-process research and development
charges
74
20
Restructuring charges and certain acquisition-related costs
499
193
2,091
1,206
Other deductions net
2,353
160
3,038
175
Income from continuing operations before provision for taxes on
income
1,440
3,971
8,593
10,823
Provision for taxes on income
564
1,092
3,198
2,952
Income from continuing operations
876
2,879
5,395
7,871
Discontinued operations net of tax
(5
(4
Net income before allocation to noncontrolling interests
871
2,881
5,391
7,877
Less: Net income attributable to noncontrolling interests
24
Net income attributable to Pfizer Inc.
866
2,878
5,367
7,868
Earnings per share basic:
Income from continuing operations attributable to Pfizer Inc.
common shareholders
0.11
0.43
0.67
1.17
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.11
0.43
0.67
1.17
Earnings per share diluted:
Income from continuing operations attributable to Pfizer Inc.
common shareholders
0.11
0.43
0.66
1.16
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.11
0.43
0.66
1.16
Weighted-average shares used to calculate earnings per common
share:
Basic
8,027
6,730
8,045
6,727
Diluted
8,057
6,762
8,079
6,758
Cash dividends paid per common share
0.18
0.16
0.54
0.64
(a)
Includes amortization of certain intangible assets, as disclosed in Note 10B. Goodwill and Other Intangible Assets: Other Intangible Assets.
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(millions of dollars)
Oct. 3,
2010
Dec. 31,
2009
(Unaudited)
Assets
Cash and cash equivalents
2,176
1,978
Short-term investments
20,288
23,991
Accounts receivable, less allowance for doubtful accounts
14,302
14,645
Short-term loans
774
1,195
Inventories
8,771
12,403
Current deferred tax assets and other current assets
7,284
6,962
Assets held for sale
494
496
Total current assets
54,089
61,670
Long-term investments and loans
10,344
13,122
Property, plant and equipment, less accumulated depreciation
19,450
22,780
Goodwill
43,787
42,376
Identifiable intangible assets, less accumulated amortization
58,627
68,015
Noncurrent deferred tax assets and other noncurrent assets
5,118
4,986
Total assets
191,415
212,949
Liabilities and Shareholders Equity
Short-term borrowings, including current portion of long-term debt
5,158
5,469
Accounts payable
3,206
4,370
Dividends payable
1,454
Income taxes payable
1,620
10,107
Accrued compensation and related items
1,853
2,242
Current deferred tax liabilities and other current liabilities
12,334
13,583
Total current liabilities
24,172
37,225
Long-term debt
39,010
43,193
Pension benefit obligations
5,196
6,392
Postretirement benefit obligations
3,258
3,243
Noncurrent deferred tax liabilities
16,940
17,839
Other taxes payable
8,578
9,000
Other noncurrent liabilities
6,193
5,611
Total liabilities
103,347
122,503
Preferred stock
54
61
Common stock
443
443
Additional paid-in capital
70,678
70,497
Employee benefit trusts
(8
(333
Treasury stock
(22,707
(21,632
Retained earnings
42,873
40,426
Accumulated other comprehensive (loss)/income
(3,698
552
Total Pfizer Inc. shareholders equity
87,635
90,014
Equity attributable to noncontrolling interests
433
432
Total shareholders equity
88,068
90,446
Total liabilities and shareholders equity
191,415
212,949
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
(millions of dollars)
Oct. 3,
2010
Sept. 27,
2009
Operating Activities:
Net income before allocation to noncontrolling interests
5,391
7,877
Adjustments to reconcile net income before allocation to noncontrolling interests to net
cash (used in)/provided by operating activities:
Depreciation and amortization
6,493
2,983
Share-based compensation expense
351
258
Asset write-offs and impairment charges
2,956
293
Benefit plan contributions (in excess of)/less than expense
(706
318
Deferred taxes from continuing operations
1,277
1,121
Other non-cash adjustments
(61
(248
Changes in assets and liabilities, net of acquisitions and divestitures
(10,505
(840
Net cash provided by operating activities
5,196
11,762
Investing Activities:
Purchases of property, plant and equipment
(966
(783
Purchases of short-term investments
(5,018
(57,148
Proceeds from redemptions and sales of short-term investments
9,493
31,747
Purchases of long-term investments
(2,674
(6,053
Proceeds from redemptions and sales of long-term investments
3,822
4,824
Other investing activities
496
508
Net cash provided by/(used in) investing activities
5,153
(26,905
Financing Activities:
Increase in short-term borrowings
4,686
28,473
Principal payments on short-term borrowings
(9,265
(29,976
Proceeds from issuances of long-term debt
23,997
Principal payments on long-term debt
(4
(910
Purchases of common stock
(1,000
Cash dividends paid
(4,544
(4,268
Other financing activities
32
(101
Net cash (used in)/provided by financing activities
(10,095
17,215
Effect of exchange-rate changes on cash and cash equivalents
(56
40
Net increase in cash and cash equivalents
198
2,112
Cash and cash equivalents at beginning of period
1,978
2,122
Cash and cash equivalents at end of period
2,176
4,234
Supplemental Cash Flow Information:
Cash paid during the period for:
Income taxes
11,519
1,748
Interest
2,039
723
See accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month and nine-month periods ended August 29, 2010, and August 23, 2009.
On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations for the third-quarter and nine-month 2010 periods, but not for the third-quarter and nine-month 2009 periods. Also, legacy Wyeth cash flows are reflected for the nine-month period in 2010, but not for the nine-month period in 2009.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2009.
Note 2. Adoption of New Accounting Policies
The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have a significant impact on our consolidated financial statements:
An amendment to the recognition and measurement guidance for the transfers of financial assets.
An amendment to the guidelines for determining the primary beneficiary in a variable interest entity.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 3. Acquisition of Wyeth
On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion.
Recording of Assets Acquired and Liabilities Assumed
The following table summarizes the final amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first nine months of 2010 to the amounts initially recorded in 2009 (measurement period adjustments). The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements.
(millions of dollars)
Amounts Recognized
as of Acquisition Date
(provisional)(a)
Measurement
Period
Adjustments
Amounts Recognized
as of Acquisition Date
(final)
Working capital, excluding inventories
16,342
37
16,379
Inventories(b)
8,388
(417
7,971
Property, plant and equipment
10,054
(216
9,838
Identifiable intangible assets, excluding
in-process research and development(b)
37,595
(1,533
36,062
In-process research and development(b)
14,918
(1,096
13,822
Other noncurrent assets
2,394
2,394
Long-term debt
(11,187
(11,187
Benefit obligations
(3,211
36
(3,175
Net tax accounts(c)
(24,773
1,058
(23,715
Other noncurrent liabilities
(1,908
(1,908
Total identifiable net assets
48,612
(2,131
46,481
Goodwill(d)
19,954
2,127
22,081
Net assets acquired
68,566
(4
68,562
Less: Amounts attributable to
noncontrolling interests
(330
(326
Total consideration transferred
68,236
68,236
(a)
As previously reported in Pfizer s 2009 Annual Report on Form 10-K.
(b)
These measurement period adjustments were recorded to reflect changes in the estimated fair value of certain intangible assets and inventories. These adjustments were made largely to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
(c)
These measurement period adjustments primarily reflect the tax impact of the pre-tax measurement period adjustments. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
(d)
Goodwill recognized as of the acquisition date totaled $19,172 million for our Biopharmaceutical segment and $2,909 million for our Diversified segment.
Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs
We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.
Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January 26, 2009, but not completed as of December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth s operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
We incurred the following costs in connection with all of our cost-reduction initiatives and the acquisition of Wyeth:
Three Months Ended
Nine Months Ended
(millions of dollars)
Oct. 3,
2010
Sept. 27,
2009
Oct. 3,
2010
Sept. 27,
2009
Transaction costs(a)
19
13
572
Integration costs(b)
231
113
650
242
Restructuring charges(c):
Employee termination costs
27
36
603
200
Asset impairments
174
17
677
108
Other
67
148
84
Restructuring charges and certain acquisition-related costs
499
193
2,091
1,206
Additional depreciation asset restructuring, recorded in our Condensed
Consolidated Statements of Income as follows(d):
Cost of sales
241
367
102
Selling, informational and administrative expenses
28
190
17
Research and development expenses
26
46
42
Total additional depreciation asset restructuring
295
10
603
161
Implementation costs(e)
70
249
Total
794
273
2,694
1,616
(a)
Transaction costs represent external costs directly related to our acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.
(b)
Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.
(c)
Restructuring charges in 2010 are related to the integration of Wyeth. From the beginning of our cost-reduction initiatives in 2005 through October 3, 2010, Employee termination costs represent the expected reduction of the workforce by approximately 46,600 employees, mainly in manufacturing, sales and research, of which approximately 33,400 employees have been terminated as of October 3, 2010. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.
(d)
Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)
Implementation costs in the three months and nine months ended September 27, 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended September 27, 2009, implementation costs are included in Cost of sales ($16 million), Selling, informational and administrative expenses ($48 million), Research and development expenses ($5 million) and Other deductions net ($1 million). For the nine months ended September 27, 2009, implementation costs are included in Cost of sales ($42 million), Selling, informational and administrative expenses ($165 million), Research and development expenses ($36 million) and Other deductions net ($6 million).
The components of restructuring charges associated with all of our cost-reduction initiatives and the acquisition of Wyeth follow:
(millions of dollars)
Costs
Incurred
2005-2010
Activity through
Oct. 3, 2010(a)
Accrual as of
Oct. 3, 2010(b)
Employee termination costs
8,324
6,387
1,937
Asset impairments
2,129
2,129
Other
858
754
104
Total restructuring charges
11,311
9,270
2,041
(a)
Includes adjustments for foreign currency translation.
(b)
Included in Current deferred tax liabilities and other current liabilities ($1.6 billion) and Other noncurrent liabilities ($482 million).
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 5. Other (Income)/Deductions Net
The following table sets forth details related to amounts recorded in Other deductions net:
Three Months Ended
Nine Months Ended
(millions of dollars)
Oct. 3, 2010
Sept. 27, 2009
Oct. 3, 2010
Sept. 27, 2009
Interest income(a)
(100
(171
(297
(620
Interest expense(a)
428
369
1,339
769
Net interest expense
328
198
1,042
149
Royalty-related income
(158
(35
(395
(142
Net gain on asset disposals
(13
(40
(243
(81
Legal matters, net(b)
712
54
886
130
Certain asset impairment charges(c)
1,478
1,710
96
Other, net
(23
38
23
Other deductions net
2,353
160
3,038
175
(a)
Interest expense increased in 2010 due to our issuance of $13.5 billion of senior unsecured notes on March 24, 2009 and approximately $10.5 billion of senior unsecured notes on June 3, 2009, primarily related to the acquisition of Wyeth as well as the addition of legacy Wyeth debt. Interest income decreased in 2010 due to lower interest rates coupled with lower average investment balances.
(b)
Legal matters, net in the three-month and nine-month periods ended October 3, 2010 includes an additional $701 million charge for asbestos litigation related to our wholly owned subsidiary, Quigley Company, Inc.
(c)
The asset impairment charges in the three-month and nine-month periods ended October 3, 2010 are primarily related to intangible assets acquired as part of our acquisition of Wyeth, including IPR&D assets, Brands and, to a lesser extent, Developed Technology Rights. See also Note 3. Acquisition of Wyeth and Note 10B. Goodwill and Other Intangible Assets: Other Intangible Assets. The impairment charges result from our current estimate of the fair value of these assets, based upon updated forecasts, compared with their assigned fair values as of the Wyeth acquisition date, October 15, 2009. The fair value of acquired identifiable intangible assets generally is determined using an income approach that starts with a forecast of all of the expected future net cash flows associated with the asset which are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Our updated forecasts of net cash flows for the impaired assets, reflect, among other things the following: for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risk associated with these assets; for Brand assets, the current competitive environment and planned investment support; and, for Developed Technology Rights, an increased competitive environment. Of these amounts, in the third quarter of 2010, about $900 million related to our Biopharmaceutical segment and $600 million related to our Diversified segment. The nine-month period of 2010 also included another $200 million in impairments related to our Biopharmaceutical segment.
Note 6. Taxes on Income
Our effective tax rate for continuing operations was 39.2% for the third quarter of 2010, compared to 27.5% for the third quarter of 2009, and 37.2% for the first nine months of 2010, compared to 27.3% for the first nine months of 2009. The higher tax rates in the third quarter and first nine months of 2010 are primarily the result of:
higher expenses incurred as a result of our acquisition of Wyeth, and the mix of jurisdictions in which those expenses were incurred;
the expiration of the U.S. research and development tax credit; and
the non-recurrence of a tax benefit of $174 million that was recorded in the third quarter of 2009 related to the final resolution of a previously disclosed settlement which resulted in the receipt of information that raised our assessment of the likelihood of prevailing on the technical merits of our tax position;
partially offset by:
the tax benefit associated with the charge incurred for asbestos litigation discussed in Note 5. Other (Income)Deductions Net.
The effective tax rate for the first nine months of 2010 was additionally impacted by the write-off of the deferred tax asset of approximately $270 million related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from changes in the U.S. healthcare legislation enacted in March 2010 concerning the tax treatment of that subsidy, effective for tax years beginning after December 31, 2012, offset by $460 million in tax benefits for the resolution of certain tax positions pertaining to prior years with various foreign tax authorities.